Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2215 - Dendritic cell vaccination in combination with docetaxel for patients with prostate cancer – a randomized phase II study


09 Oct 2016


Poster display


Per Kongsted


Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378


P. Kongsted1, E. Ellebæk2, T.H. Borch1, T.Z. Iversen2, R. Andersen1, Ö. Met1, M. Hansen1, L. Sengeløv2, I.M. Svane1

Author affiliations

  • 1 Department Of Hematology And Oncology, Center for Cancer Immune Therapy, Herlev University Hospital, 2730 - Herlev/DK
  • 2 Department Of Oncology, Herlev University Hospital, 2730 - Herlev/DK


Abstract 2215


In this study we investigate whether the addition of an autologous dendritic cell (DC) based cancer vaccine provokes an immune response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel based chemotherapy.


43 patients were randomized 1:1 to receive up to 10 cycles of docetaxel alone, 75 mg/m2/q3 weeks or in combination with an autologous DC based vaccine. CD14+ monocytes were initially isolated from patients randomized to combinational therapy following a leukapheresis procedure. Harvested cells were incubated with GM-CSF and IL-4 and the resulting immature DCs were further matured using IL-1ß, TNFα, IL-6 and PGE2. mRNA encoding prostate specific antigen, prostatic acid phosphatase, survivin and hTERT was transfected into mature DCs using electroporation. Vaccines were administered intradermally at day 8 and 15 through treatment cycles 1 - 4 and at day 8 only through treatment cycles 5 – 10. Delayed type hypersensitive (DTH) tests were applied. Immune cell composition and antigen specific responses in blood samples were analyzed using flow cytometry and ELISPOT. Prostate cancer clinical trials working group 2 guidelines were followed. Toxicity was graded according to CTCAE version 4.0. Progression free survival (PFS) and disease specific survival (DSS) was calculated using the Kaplan-Meier method.


Baseline mCRPC prognostic factors were equally distributed in the two treatment groups. Median number of treatment cycles was 7. Rates of 50% PSA-responses were 63% vs 38% (p = 0.11) in the docetaxel alone (n = 19) and combinational therapy group (n = 21), respectively. Median PFS and DSS was 5.5 vs 5.7 months (p = 0.62, log-rank) and 24.7 vs 25.1 months (p = 0.70, log-rank). Vaccine induced toxicity was limited to mild local skin reactions and pain. Analysis of chemotherapy induced toxicity, DTH and immune monitoring is currently ongoing and will be presented.


The addition of an autologous DC based cancer vaccine was safe in this study. Survival endpoints were similar in both groups of patients investigated.

Clinical trial identification

ClinicalTrials.gov NCT01446731

Legal entity responsible for the study



Center for Cancer Immune Therapy and Department of oncology, Herlev University Hospital


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings